Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
EUDA Health Holdings ( (EUDA) ) has issued an update.
On January 15, 2026, EUDA Health Holdings announced that it had entered into a second amendment to its warrant agreement with Streeterville Capital, LLC, dated January 13, 2026, further cutting the warrant exercise price from US$4.00 to US$2.00 per share and lowering the minimum share price required to trigger a forced exercise from US$6.00 to US$3.00, while leaving all other terms unchanged. Management characterized the move as a technical adjustment to better align the warrant terms with current market conditions and to preserve flexibility in the company’s capital structure, signalling that the change is not expected to alter EUDA’s long-term strategic or operational priorities but may influence how it manages equity financing and shareholder dilution going forward.
The most recent analyst rating on (EUDA) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on EUDA Health Holdings stock, see the EUDA Stock Forecast page.
More about EUDA Health Holdings
EUDA Health Holdings Limited is a Singapore-based provider of non-invasive and preventive healthcare services across Asia, with a core focus on Singapore, Malaysia and China. The company is targeting the fast-growing longevity sector by offering innovative, accessible, science-backed health solutions aimed at shifting regional healthcare from reactive treatment to proactive, longevity-focused care, and it also operates a Singapore-based property management business.
Average Trading Volume: 487,738
Technical Sentiment Signal: Sell
Current Market Cap: $72.21M
For a thorough assessment of EUDA stock, go to TipRanks’ Stock Analysis page.